Newsroom

Blog

NeoGenomics announces speaker program, ‘Minimal Residual Disease in Colorectal Cancer’

NeoGenomics is pleased to announce a speaker program titled ‘Minimal Residual Disease in Colorectal Cancer.’

Read More

IVDR at NeoGenomics

With the recent application of IVDR on May 26, 2022, there are new regulatory standards that oversee the sales and use of IVDs for the EU.

Read More

NeoGenomics Hurricane Ian Emergency Response

as of 6:00pm ET

 

Dear Valued Client,

Read More

NeoGenomics Lab Operations | Hurricane Ian

Important Announcement

NeoGenomics Lab Operations | Hurricane Ian

Read More

Orphan CDx assays

Drug development is rapidly outpacing our ability to bring companion diagnostics to market.

Read More

MultiOmyx 101: An Introduction to Multiplexing Technology

Cancer claims more than half a million lives each year in the United States alone.

Read More
Written By:
AnnaJunckerJensen.jpg
Anna Juncker-Jensen

Comprehensive Genomic Profiling (CGP) expands precision medicine’s utility

With the first TKI therapy Imatinib (Gleevec) targeting the fusion BCR-ABL1, approved by FDA in 2001, we have witnessed the birth of modern targeted therapy and personalized medicine.

Read More
Written By:
QinqinZha.jpg
Qinqin Zha

Diagnostic Symposium

Join NeoGenomics for our upcoming Diagnostic Symposium on Tuesday, May 10, 9 to 10 a.m. PT.

Read More

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients